Protara Therapeutics (TARA)

• Market cap: $123M
• 1 day: -4.50%
• 5 days: -6.19%
• 1 month: 4.95%
• 3 months: -9.14%
• 6 months: -29.33%
• Year to date: -43.01%
• 1 year: 43.89%
• 5 years: -87.66%
• 10 years: -99.53%
• Sector: Healthcare
• Industry: Biotechnology

About: Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Employees: 33

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

363% more call options, than puts

Call options by funds: $2.21M | Put options by funds: $478K

100% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 12

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]

2% less funds holding

Funds holding: 60 [Q4 2024] → 59 (-1) [Q1 2025]

8.24% less ownership

Funds ownership: 86.45% [Q4 2024] → 78.22% (-8.24%) [Q1 2025]

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

21% less capital invested

Capital invested by funds: $157M [Q4 2024] → $124M (-$32.8M) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $21 560% upside
• Avg. target: $21 560% upside
• High target: $21 560% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Jones Trading Soumit Roy

560% upside $21

Buy Initiated

22 May 2025